GLS2
Basic information
Region (hg38): 12:56470944-56488414
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GLS2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 18 | 20 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 0 | |||||
Total | 0 | 0 | 18 | 2 | 1 |
Variants in GLS2
This is a list of pathogenic ClinVar variants found in the GLS2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
12-56471555-G-A | not specified | Uncertain significance (Jun 22, 2021) | ||
12-56471611-T-A | not specified | Uncertain significance (Mar 19, 2024) | ||
12-56471836-C-T | not specified | Uncertain significance (May 31, 2023) | ||
12-56473229-C-T | not specified | Uncertain significance (Nov 27, 2023) | ||
12-56473266-G-A | not specified | Uncertain significance (Jun 02, 2023) | ||
12-56473561-C-T | not specified | Uncertain significance (Nov 08, 2022) | ||
12-56474590-A-C | not specified | Uncertain significance (May 16, 2024) | ||
12-56474667-G-A | Likely benign (May 01, 2022) | |||
12-56474684-C-T | not specified | Uncertain significance (Jun 11, 2021) | ||
12-56474882-C-T | Benign (Mar 29, 2018) | |||
12-56475067-C-T | not specified | Uncertain significance (Oct 18, 2021) | ||
12-56475081-C-T | not specified | Uncertain significance (Jan 24, 2024) | ||
12-56475621-T-C | Likely benign (Apr 10, 2018) | |||
12-56475643-T-C | not specified | Uncertain significance (Jun 29, 2023) | ||
12-56475655-C-T | not specified | Uncertain significance (May 25, 2022) | ||
12-56477954-T-G | not specified | Uncertain significance (Sep 12, 2023) | ||
12-56477955-G-C | not specified | Uncertain significance (Sep 12, 2023) | ||
12-56478013-A-C | not specified | Uncertain significance (Jan 30, 2024) | ||
12-56478028-A-G | not specified | Uncertain significance (May 24, 2023) | ||
12-56479090-G-A | not specified | Uncertain significance (Feb 26, 2024) | ||
12-56479795-C-T | not specified | Uncertain significance (Dec 03, 2021) | ||
12-56480313-C-T | not specified | Likely benign (Sep 20, 2023) | ||
12-56480370-C-T | not specified | Uncertain significance (Dec 17, 2021) | ||
12-56488102-G-A | not specified | Uncertain significance (Nov 18, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GLS2 | protein_coding | protein_coding | ENST00000311966 | 18 | 17463 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.32e-10 | 0.985 | 125670 | 0 | 78 | 125748 | 0.000310 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.35 | 221 | 344 | 0.643 | 0.0000185 | 3940 |
Missense in Polyphen | 58 | 103.41 | 0.56086 | 1159 | ||
Synonymous | 0.0718 | 126 | 127 | 0.992 | 0.00000650 | 1158 |
Loss of Function | 2.38 | 22 | 37.8 | 0.582 | 0.00000230 | 395 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000749 | 0.000749 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000652 | 0.000653 |
Finnish | 0.0000464 | 0.0000462 |
European (Non-Finnish) | 0.000366 | 0.000325 |
Middle Eastern | 0.000652 | 0.000653 |
South Asian | 0.000328 | 0.000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Plays an important role in the regulation of glutamine catabolism. Promotes mitochondrial respiration and increases ATP generation in cells by catalyzing the synthesis of glutamate and alpha-ketoglutarate. Increases cellular anti-oxidant function via NADH and glutathione production. May play a role in preventing tumor proliferation. {ECO:0000269|PubMed:20378837}.;
- Pathway
- Alanine, aspartate and glutamate metabolism - Homo sapiens (human);Central carbon metabolism in cancer - Homo sapiens (human);GABAergic synapse - Homo sapiens (human);Glutamatergic synapse - Homo sapiens (human);D-Glutamine and D-glutamate metabolism - Homo sapiens (human);Proximal tubule bicarbonate reclamation - Homo sapiens (human);MicroRNAs in cancer - Homo sapiens (human);Arginine biosynthesis - Homo sapiens (human);Warburg Effect;Argininemia;2-Hydroxyglutric Aciduria (D And L Form);Ammonia Recycling;Citrullinemia Type I;Carbamoyl Phosphate Synthetase Deficiency;Argininosuccinic Aciduria;Urea Cycle;Glutaminolysis and Cancer;The oncogenic action of 2-hydroxyglutarate;Homocarnosinosis;The oncogenic action of L-2-hydroxyglutarate in Hydroxygluaricaciduria;The oncogenic action of D-2-hydroxyglutarate in Hydroxygluaricaciduria ;Hyperinsulinism-Hyperammonemia Syndrome;Succinic semialdehyde dehydrogenase deficiency;Ornithine Transcarbamylase Deficiency (OTC Deficiency);4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;Glutamate Metabolism;TP53 Regulates Metabolic Genes;Gene expression (Transcription);Generic Transcription Pathway;Glutamate Glutamine metabolism;Metabolism of amino acids and derivatives;RNA Polymerase II Transcription;Metabolism;glutamine degradation/glutamate biosynthesis;Neuronal System;TP53 Regulates Metabolic Genes;Urea cycle and metabolism of arginine, proline, glutamate, aspartate and asparagine;Glutamate Neurotransmitter Release Cycle;Neurotransmitter release cycle;Transcriptional Regulation by TP53;Transmission across Chemical Synapses;Amino acid synthesis and interconversion (transamination)
(Consensus)
Recessive Scores
- pRec
- 0.281
Intolerance Scores
- loftool
- 0.778
- rvis_EVS
- -0.54
- rvis_percentile_EVS
- 20.54
Haploinsufficiency Scores
- pHI
- 0.677
- hipred
- Y
- hipred_score
- 0.563
- ghis
- 0.561
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.740
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gls2
- Phenotype
Gene ontology
- Biological process
- cellular amino acid metabolic process;glutamate biosynthetic process;glutamine catabolic process;cellular amino acid biosynthetic process;glutamate secretion;regulation of apoptotic process;reactive oxygen species metabolic process
- Cellular component
- mitochondrion;mitochondrial matrix
- Molecular function
- glutaminase activity;protein binding